To obtain an insight into the transcription factor (TF)-dependent regulation of epiblast stem cells (EpiSCs), we performed ChIP-seq analysis of the genomic binding sites in EpiSCs of five major TFs, ZIC2, OTX2, SOX2, POU5F1, and POU3F1, using biotinylated TFs, identifying the following new features: (1) The genomic domains of megabase scale rich in ZIC2 peaks and genes, and those rich in POU3F1 but sparse in genes, alternate in EpiSCs, reflecting the clustering of regulatory regions that act in short-and long-ranges, which involve binding of ZIC2 and POU3F1, respectively. (2) Mouse embryonic stem cells (ESCs) are established from the inner cell mass (ICM) of lastocyst and sustains pluripotent state. In contrast, ICM loses pluripotency gradually along the development in vivo. These results strongly suggest that some molecular events should take place to capture the sustainable pluripotency of ESCs. We tried to reveal the molecular mechanism underling the establishment of sustainable pluripotency of ESCs.
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Mouse embryonic stem cells (ESCs) are established from the inner cell mass (ICM) of lastocyst and sustains pluripotent state. In contrast, ICM loses pluripotency gradually along the development in vivo. These results strongly suggest that some molecular events should take place to capture the sustainable pluripotency of ESCs. We tried to reveal the molecular mechanism underling the establishment of sustainable pluripotency of ESCs.
First, we confirmed that pluripotent state could be maintained under the serum-free medium containing only low concentration of GSK3 inhibitor and LIF (LowGiL condition). The ESCs cultured under the LowGiL condition, hereafter LowGiL-ESCs, expressed pluripotent markers and contributed to chimeric embryos, including germ cells at comparable levels to the ESCs cultured under the 2iL condition (2iL-ESCs). However, LowGiL condition was insufficient to establish ESCs, which was due to the spontaneous differentiation during the culture. Although there was not significant difference in colony morphology, the expression levels of pluripotent markers (Nanog, Oct4 and Sox2) were significantly decreased in the LowGiL condition than that in the 2iL condition at day 7 of culture. Meanwhile, culture of blastocyst cells during the first 3 days under the 2iL condition brought about the pluripotent state and subsequent stable pluripotency even under the LowGiL condition. Transcriptome analysis of ICM and 3-dayscultured ICM under the 2iL condition revealed the significant upregulation of the pluripotent markers, including Sox2 and Nr0b1. Considering that up-regulation of these genes was not observed with the LowGiL-condition, it is quite likely that these activations are the molecular basis of the induction of sustainable pluripotency. Pharmaceuticals and chemicals are primarily metabolized in the liver. Drug-induced liver injury (DILI) remains a leading cause of new drug withdrawal from human clinical trials. Therefore, a hepatic platform mimicking liver physiology is perceived for drug development. Hepatocytes differentiated from human embryonic stem cells (ESCs) or human induced pluripotent stem cells (iPSCs) are expected to be useful for the prediction of DILI in drug development. However, the actual applicability is hampered by the limited availability of metabolically functioning hepatocytes derived from human pluripotent stem cells (PSCs). In order to generate hepatocytes expressing drug-metabolizing enzymes from PSCs that would be applicable for drug hepatotoxicity testing, the current work tried to enhance metabolic function of ESC-derived hepatocytes via employing microRNAs differentially expressed in primary human hepatocytes. We initially setup protocols to differentiate human ESCs and iPSCs to hepatocyte-like cells. MicroRNA expression profiling and real-time quantitative PCR analysis were then conducted in PSC-derived hepatocyte-like cells and primary human hepatocytes. 24 miRNAs we found to express at high levels in primary hepatocytes compared to PSC-derived hepatocyte-like cells. We validated expression of seven miRNAs including hsa-miR-664a-3p, hsa-miR-194-3p, hsamiR-29c-5p, hsa-miR-4662a-5p, hsa-miR-885-5p, hsa-miR-126-5p, hsa-miR-122-3p and found transfection of hsa-miR-194-3p, hsamiR-126-5p, and hsa-miR-122-3p can significantly enhance the expression levels of the metabolizing enzymes such as CYP1A2, CYP2C9, UGT1A9, UGT2B4, and promote these enzymes activity in both HepG2/C3A cells and PSC-derived hepatocyte-like cells. Hopefully, the findings from the current work can lead to develop a strategy that can enhance metabolic function of PSC-derived hepatocyte-like cells. And these PSC-derived hepatocyte-like cells can be used for the prediction of DILI in drug development in the near future. 
